article thumbnail

Exosomes: A Deeper Look into Service Providers Market

Roots Analysis

Broad Clinical Trial Landscape. Till date, over 180 clinical studies which primarily include completed, ongoing and planned trials evaluating various clinical research activity related to exosomes and involving nearly 2,392 patients enrolled across different centers / hospitals, have been initiated worldwide. Web: [link].

article thumbnail

Oral Protein / Peptide-based Drugs: Addressing Key Unmet Needs Across Disease Indications

Roots Analysis

With four commercialized therapies and over 120 clinical / preclinical development programs, oral protein and peptide therapies represent a lucrative segment of the pharmaceutical industry. Oral Protein / Peptide-based Drugs. Clinical Research Landscape of Oral Peptide and Protein-based Therapeutics. Web: [link].

Protein 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Role of the Data Safety Monitoring Board (DSMB) in Clinical Trials

Cloudbyz

A Data Safety Monitoring Board (DSMB) is an independent committee composed of clinical research experts, statisticians, and often, ethicists. It typically includes clinicians familiar with the disease area and treatment under investigation, biostatisticians with expertise in clinical trials, and often ethicists or patient advocates.

article thumbnail

Next Generation Complement Therapeutics: Potential Life-Changing Therapies for Multiple Rare Disorders

Roots Analysis

Owing to the fact that the complement system is a multidimensional innate immune surveillance system, more novel therapeutic targets are likely to be discovered in the future, with the active involvement of big pharma players as well as new pharma entrants. For further information on this domain, check out the report –. Web: [link].

article thumbnail

Unlocking the potential of mucoadhesive drug delivery

Drug Discovery World

At each stage, there is a continued process of attrition that ultimately limits the number of new APIs making it to the clinical phases, and approximately 90% of new drug candidates advancing to clinical trials fail to achieve final drug approval 2,3. . Consider drug delivery systems early on .

article thumbnail

Metabolomics: An Emerging yet Powerful Tool in Clinical Research and Development

Roots Analysis

You may also be interested in the following titles: Continuous Manufacturing (Small Molecules and Biologics) Market Subcutaneous Biologics, Technologies and Drug Delivery Systems Market Antibody Discovery Services and Platforms Market. Our Social Media Platform. Web: [link]. LinkedIn: [link]. Twitter: [link].

article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. In a recent webinar, Dr. Vornov described the history and current progress in targeted CNS therapeutic delivery.

Trials 83